Effectiveness of PARP inhibitors in ovarian cancer

The Cancer Genome Atlas and high grade serous ovarian cancer

6th International Workshop on Myeloma Pharmacogenomics and Novel Therapeutics

Progress of personalised oncology treatment

Pathology and development of ovarian cancer

Putting the theory of personalised medicine into practice

Treatment of ALK+ lung cancer with crizotinib, Profile 1007

Phase III MISSION trial: Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer

Personalised cancer medicine and research: Today’s best practice

Putting drugs to work against brain metastases in HER2 positive breast cancer: LANDSCAPE study

Biomarker analysis of MISSION: EGFR lung tumours may benefit from sorafenib

Highlights from the 2012 NCID Meeting